期刊
ACS CHEMICAL NEUROSCIENCE
卷 8, 期 5, 页码 973-986出版社
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.6b00440
关键词
5-HT; Parkinson's disease; clinical; animal models; dyskinesia
资金
- Western Brain Institute
- Parkinson Society Canada
- Natural Sciences and Engineering Research Council of Canada
- Fonds de Recherche Qubec Sant
- Fondation de France [201234497, 00016818]
- Astra Zeneca
- Avanir
- Biotie
- C2N
- Cynapsus
- Kyowa
- Orion
- MJFF for PD research
- NIH
- Toronto Western Foundation
Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the dopaminergic system, leading to the classic motor manifestations of the disease. However, there is now overwhelming evidence that PD is more than a disease merely caused by dopamine depletion. It is well-known that a myriad of other neurotransmitters are affected by the disease process. One such neurotransmitter is serotonin (5-HT). 5-HT has been shown to play a role in several motor and nonmotor manifestations of PD, including tremor, cognition, depression and psychosis. 5-HT also seems to play a critical role in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. A breadth of preclinical studies and clinical trials have been conducted that aimed at modulating the 5-HT system in order to alleviate depression, cognitive deficits, psychosis, and dyskinesia. In this Review, we summarize recent advances in the 5-HT field in PD, but with a translational emphasis. We start by presenting a novel nonhuman primate model of PD that presents with dual dopamine and 5-HT lesions. We then present preclinical and clinical data that introduce new concepts, such as the use of biased and partial agonists, as well as molecules recently introduced to the field of PD, such as eltoprazine, pimavanserin, nelotanserin, and SYN-120, to enhance therapeutic benefit while minimizing adverse events, notably on parkinsonian disability.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据